Thursday November 23, 2017 14:11

Heathcare Press Release : 14 Nov 2017

Photo Release: The Royal Danish Embassy and Novo Nordisk Pharma (Thailand) Co., Ltd launch the Blueprint for Change address Diabetes challenge , aligned with national NCD targets Heathcare—14 Nov 17

On the 5th November 2017, right after the WDD event at the Vachirabenjatas Park (Suan Rot Fai Park) . Mr.Uffe Wolffhechel, the ambassador of the Royal Danish Embassy, Thailand (right) together with Mr.Mihai Irimescu, General Manager of Novo Nordisk

Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine Heathcare—14 Nov 17

KALAMAZOO, Michigan, USA--14 Nov--PRNewswire/InfoQuest

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from an ischemic stroke receives thrombectomy, due in part to a lack of scientific evidence supporting treatment beyond six hours. The results shown in the DAWN trial have the potential to fundamentally change the paradigm of care for stroke patients globally.

According to Dr. Tudor Jovin, co-principal investigator from the University of Pittsburgh Medical Center, "By quadrupling the size of the therapeutic time window, the consequence of DAWN is that many more patients with large vessel occlusion stroke have the potential to be treated with mechanical thrombectomy.   DAWN validates the physiological, rather than time-based approach to patient selection for endovascular therapy."

"Time alone should no longer be a disqualifier for thrombectomy but rather only a source of urgency.   We hope this new treatment paradigm will benefit a large proportion of patients who were previously deemed untreatable," commented Dr. Raul Nogueira, Professor of Neurology, Neurosurgery and Radiology at Emory University School of Medicine and Director of

UMIT Professor Uwe Siebert Receives SMDM Award and Becomes SMDM President Heathcare—14 Nov 17

At the 39th Annual Society for Medical Decision Making (SMDM) Conference in Pittsburgh, PA, Professor Uwe Siebert received the SMDM Award for Distinguished Service and was inaugurated as 2017-2018 SMDM President. (Photo:

Johnson Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Heathcare—14 Nov 17

Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., today announced the launch of the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel,

Kaneka Nutrients announces The International Coenzyme Q10 Association Ninth Scientific Heathcare—14 Nov 17

The International Coenzyme Q10 Association (ICQA; http://icqaproject.org/ ) is a non-profit organization that fosters basic and applied biomedical research on Coenzyme Q10 (CoQ10). Their mission is to advance knowledge on basic biochemistry and molecular

Merck Receives FDA Approval for New GONAL-f(R) Prefilled Pen Heathcare—14 Nov 17

- New pen is easy-to-learn and easy-to-use, supporting the one in six couples affected by infertility in the U.S.[1] - Insights of patients, nurses and doctors helped to evolve the product Merck, a leading science and technology company, today announced

GENOMICA Receives Authorization for the Commercialization of its Diagnostic Kits and Instruments in Heathcare—14 Nov 17

GENOMICA, a leading molecular diagnostics company belonging to the PharmaMar Group (MCE: PHM), has announced that it has received authorization in South Korea for commercializing CLART(R) in vitro diagnostic kits together with the autoclart(R) plus